Status:
UNKNOWN
Anti-reflux Mucosectomy (ARMS) is a Useful Therapy for Refractory Gastroesophageal Reflux Disease (RGERD)
Lead Sponsor:
Ruihua Shi
Conditions:
Refractory Gastroesophageal Reflux Disease
Eligibility:
All Genders
Phase:
NA
Brief Summary
Anti-reflux mucosectomy (ARMS) may be a new therapy for refractory gastroesophageal reflux disease (RGERD). The aim of the present study is to explore the safety and efficacy of ARMS.
Eligibility Criteria
Inclusion
- Full sufficiency in literacy
- Be off proton pump inhibitor, antacids and prokinetics ≥ 2 weeks
- Refractory gastroesophageal reflux disease
Exclusion
- Severe heart, lung, and cerebrovascular disease
- Severe hematopoietic system disease
- Abnormal blood coagulation function
- Oropharyngeal abnormalities
- Severe spine malformation
- In pregnancy and lactation at present, or plan to become pregnant within 2 years
- Severe inflammation or huge ulcers in stomach
- Mental and psychological disorde
Key Trial Info
Start Date :
August 20 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2020
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03259191
Start Date
August 20 2017
End Date
August 31 2020
Last Update
August 23 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China